587 related articles for article (PubMed ID: 24901467)
1. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction versus corticosteroid induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
4. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD007606. PubMed ID: 29630730
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
11. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D supplementation for chronic liver diseases in adults.
Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
14. Nitazoxanide for chronic hepatitis C.
Nikolova K; Gluud C; Grevstad B; Jakobsen JC
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
[TBL] [Abstract][Full Text] [Related]
15. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
17. Aminoadamantanes for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
[TBL] [Abstract][Full Text] [Related]
18. Nutrition support in hospitalised adults at nutritional risk.
Feinberg J; Nielsen EE; Korang SK; Halberg Engell K; Nielsen MS; Zhang K; Didriksen M; Lund L; Lindahl N; Hallum S; Liang N; Xiong W; Yang X; Brunsgaard P; Garioud A; Safi S; Lindschou J; Kondrup J; Gluud C; Jakobsen JC
Cochrane Database Syst Rev; 2017 May; 5(5):CD011598. PubMed ID: 28524930
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
